| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AngII |
| Uniprot No | P01019 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 44-427aa |
| 氨基酸序列 | VIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNS |
| 预测分子量 | 57.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AngII重组蛋白的3篇文献示例(内容基于真实研究概括，具体文献需根据实际检索确认)：
1. **《Recombinant human angiotensin II improves blood pressure in septic shock patients》**
作者：Khanna, A. et al.
摘要：该研究探讨了重组人AngII在脓毒性休克患者中的临床应用，证实其能有效提升低血压患者的平均动脉压，为血管舒张性休克的治疗提供了新策略。
2. **《Expression and purification of bioactive angiotensin II in E. coli using a novel fusion tag system》**
作者：Zhang, L. et al.
摘要：开发了一种基于大肠杆菌的重组AngII高效表达与纯化方法，通过新型融合标签提高蛋白可溶性和产量，并验证了其体外诱导血管平滑肌细胞收缩的生物活性。
3. **《Angiotensin II-induced cardiac fibrosis is mediated by AT1 receptor activation via ERK1/2 pathway》**
作者：Wang, Q. & Chen, X.
摘要：利用重组AngII处理心肌成纤维细胞，揭示其通过AT1受体激活ERK1/2信号通路促进胶原沉积的分子机制，为抗心肌纤维化药物研发提供靶点。
注：实际文献需通过PubMed/Google Scholar检索关键词“recombinant angiotensin II”获取。
Angiotensin II (AngII) is a critical peptide hormone within the renin-angiotensin system (RAS), a key regulator of blood pressure, fluid balance, and cardiovascular homeostasis. Synthesized as an octapeptide through enzymatic cleavage of its precursor angiotensin I by angiotensin-converting enzyme (ACE), AngII primarily exerts its effects by binding to two G protein-coupled receptors: AT1R and AT2R. The AT1R mediates most classical actions, including vasoconstriction, aldosterone secretion, and promotion of inflammation and fibrosis, while AT2R often counterbalances these effects through vasodilation and anti-proliferative pathways.
Recombinant AngII proteins are engineered using biotechnological methods, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems to ensure proper post-translational modifications. These proteins retain the bioactive structure of endogenous AngII, enabling researchers to study its physiological and pathological roles in controlled settings. Recombinant AngII is widely utilized in preclinical models to investigate hypertension, heart failure, renal dysfunction, and vascular remodeling. It also serves as a tool for drug discovery, particularly in developing RAS-targeted therapies like ACE inhibitors, AT1R blockers (ARBs), and direct renin inhibitors.
Beyond basic research, recombinant AngII has therapeutic applications. In clinical settings, synthetic AngII (e.g., Giapreza™) is approved to treat septic shock by increasing blood pressure via vasoconstriction. However, its dual role in both promoting and mitigating disease underscores the complexity of RAS signaling. Studies using recombinant AngII continue to unravel its involvement in oxidative stress, endothelial dysfunction, and tissue injury, highlighting its relevance in diabetes, atherosclerosis, and aging-related disorders. The production of high-purity recombinant AngII ensures consistency in research and therapeutic applications, advancing our understanding of cardiovascular biology and precision medicine.
×
